Future Oncology
Scope & Guideline
Bridging laboratory innovation with clinical excellence.
Introduction
Aims and Scopes
- Clinical Trials and Therapeutic Innovations:
The journal publishes studies related to clinical trials of new drugs, treatment combinations, and therapeutic strategies. This includes research on immunotherapy, targeted therapies, and combination treatments for various cancers. - Real-World Evidence and Patient Outcomes:
Future Oncology emphasizes the importance of real-world data in understanding treatment effectiveness and patient experiences. Studies often explore treatment patterns, healthcare resource utilization, and the economic burden associated with cancer therapies. - Biomarkers and Personalized Medicine:
Research focusing on the identification and validation of biomarkers for cancer diagnosis, prognosis, and treatment response is a core area. The journal supports the development of personalized medicine approaches tailored to individual patient profiles. - Quality of Life and Patient-Centered Care:
The journal addresses the psychosocial aspects of oncology, including quality of life assessments, patient-reported outcomes, and the impact of cancer treatments on patients' daily lives. - Emerging Technologies and Methodologies:
Future Oncology covers advancements in technology such as artificial intelligence, machine learning, and liquid biopsies that aim to enhance cancer diagnosis, monitoring, and treatment.
Trending and Emerging
- Immunotherapy and Combination Treatments:
There is an increasing focus on immunotherapy, particularly the combination of immunotherapeutic agents with other modalities. Research in this area highlights the potential for synergistic effects to improve patient outcomes. - Precision Medicine and Genomic Profiling:
The trend towards precision medicine is reflected in the growing number of studies exploring genomic profiling and biomarker-driven therapies, aiming to tailor treatments to individual patients based on their genetic makeup. - Real-World Data and Patient-Centric Research:
Emerging themes emphasize the collection and analysis of real-world data to inform treatment decisions, improve care pathways, and enhance patient engagement in their own treatment journeys. - Health Disparities and Access to Care:
Research addressing health disparities in cancer care and the need for equitable access to innovative treatments is gaining traction, reflecting a broader societal focus on social determinants of health. - Technological Advancements in Cancer Care:
The integration of new technologies, such as artificial intelligence in diagnostics and treatment planning, is becoming a significant focus, as these advancements promise to revolutionize oncology practice.
Declining or Waning
- Traditional Chemotherapy Studies:
There is a noticeable decline in publications focusing solely on traditional chemotherapy regimens. As targeted therapies and immunotherapies gain prominence, studies purely centered on chemotherapy alone are becoming less frequent. - Single-Agent Studies:
Research on the efficacy of single-agent therapies is decreasing, as the field moves towards combination therapies that harness synergistic effects for better outcomes. - Basic Science Research:
While foundational research remains important, there is a shift away from purely basic science studies towards clinical application and translational research that directly impacts patient care. - Older Treatment Modalities:
Publications focusing on older treatment modalities, such as older radiotherapy techniques or conventional surgical approaches, are diminishing as newer, less invasive techniques and personalized strategies come to the forefront. - Epidemiological Studies without Clinical Implications:
Epidemiological studies that do not translate into actionable clinical insights or interventions are less frequently published, as the journal prioritizes impactful research that informs clinical practice.
Similar Journals
International Journal of Clinical Oncology
Driving Progress in Clinical Practices and ResearchInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.
Clinical Lung Cancer
Empowering clinicians with cutting-edge lung cancer studies.Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.
npj Precision Oncology
Shaping Tomorrow's Cancer Treatments Todaynpj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.
Therapeutic Advances in Medical Oncology
Fostering innovation in cancer therapies worldwide.Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.
Clinical Genitourinary Cancer
Innovating research for a healthier tomorrow.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Transforming knowledge into practice in cancer care.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.
World Journal of Gastrointestinal Oncology
Illuminating the complexities of gastrointestinal cancer research.World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.
Translational Oncology
Transforming Cancer Insights into Clinical SolutionsTranslational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.
Hepatic Oncology
Advancing the Frontiers of Liver Cancer ResearchHepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.
Oncology Research and Treatment
Empowering the future of oncology with cutting-edge insights.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.